PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study - Moskowitz, A J; Schöder, H; Yahalom, J (The Lancet Oncology, 2015)
et al.